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INTRODUCTION 
 Strokes are one of the most common causes of mortality and long 
term severe disability. There is evidence that lipoprotein [a] is a predictor 
of many terms of vascular disease. Several studies have evaluated the 
association between Lipoprotein[a] and ischemic stroke. 
THE STRUCTURE OF Lp[a]:  
Lipoprotein[a] is an LDL like molecule consisting of an apoprotein 
[apo] B-100 particle attached by a disulphide bridge to apo[a] (1) APO[a] 
is a member of a family of “Kringle” containing proteins. Such as 
plasminogen, tissue platelet activates [TPA], prothrombin factor XII, 
macrophage stimulating factor [MSF] (2,3). Lipoprotein[a] shares high 
degree of identity with plasminogen (2,4). 
 The apo(a) gene is highly polymorphic and more than 34 different 
sized alleles have been identified (5) molecular weights range from 187 
to 648 DC. 
 The accumulation of Lipoprotein[a] molecule has been 
demonstrated in arterial walls of human cerebral vessels (6). This affinity 
may be  attributed to the affinity may be attributed to the tendency of apo 
(a) to bind to connective tissue elements such as proteoglycans, 
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glycosaminoglycans, and fibronectin (7). The binding process is 
promoted by lipoprotein lipase or sphingomyelinase (8). Lipoprotein[a] 
competes with plasminogen for its receptors on endothelial cells, leading 
to diminished plasma formation, thereby delaying clot lyses and 
favouring thrombosis (9). 
 It has been suggested that apo [a] can cause endothelial dysfunction 
by enhancing lipid deposition in vessel walls inhibiting fibrinolysis and 
modulating smooth muscle cell proliferation (10). Raised Lipoprotein[a] 
concentrations were a significant determinant on the extent of carotid 
atherosclerosis. Therefore the estimation of lipoprotein[a] might help 
identify patients with an increased risk of stroke (11). 
 Dietary modifications is thought to influence Lipoprotein[a] 
values. A diet rich in palm oil has been reported to reduce Lipoprotein[a] 
concentration by approximately 10% (12). Nicotinic acid is said to have 
favourable effect on Lipoprotein[a] concentration (13) (14). Statins are 
said to increase Lipoprotein[a]. Fibrates are said to decrease 
Lipoprotein[a] levels (15) (16). Optimizing weight and tight glycemic 
control may beneficially influence Lipoprotein(a) values in patients with 
type 1 and type 2. diabetes (17). This effect is linked to triglyceride 
metabolism which is impaired in type 2  diabetes mellitus as well as 
glycosylation of Lipoprotein[a] which interferes with its catabolism (17). 
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 This study is designed to evaluate the association of Lipoprotein(a) 
in patients with diabetes mellitus who have suffered an ischemic stroke. 
AIM OF STUDY: 
 The aim of this study is to investigate the serum lipoprotein [a] 
levels in 38 cases of stroke patients with diabetes mellitus and to 
determine the consistency of its association when compared with 38 
statistically matched diabetic individuals as controls. 
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REVIEW OF LITERATURE: 
 Lipoprotein [a] is a circulating lipoprotein that resembles LDL 
cholesterol in core lipid composition and in having apo B 100 as a surface 
apolipoprotein. Apo [a] is bound to apo B-100 by a disulphide bond (18). 
Apo [a] is a glycosylated protein that resembles plasminogen and is 
composed of serial Kringle domain (19). The physiological function of 
Lipoprotein[a] remains obscure, although a role in wound healing is 
proposed (20). Plasma levels of Lipoprotein[a] vary widely among 
individuals, are generally unrelated to those of other lipoproteins and 
apolipoproteins (21) and appear to be highly heritable (22). Risk of 
cardiovascular events appear to be increased when plasma levels exceed 
20 to 30 mg /dl (23). 
 Non genetic mechanisms which regulate serum Lipoprotein[a] 
levels are unknown, although levels are increased in people with renal 
insufficiency, nephritic syndrome, diabetes and in menopausal women. 
 Ethnicity plays a major role in Lipoprotein[a] levels. African 
Americans have higher median levels of Lipoprotein[a] than white people 
(24) possibly due to transcription of the apo [a] gene or increased 
secretion of apo [a] (25). Elevated Lipoprotein[a] levels may be more 
atherogenic in presence of small apo [a] size [ <22 Kringle – 4 repeats] 
V/s larger apo [a] isoforms (26). In African Americans, high 
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Lipoprotein[a] levels are less likely to be associated with the presence of 
small apo [a] isoforms than in white people (27). 
The factors influencing serum Lp(a) concentrations are given below: 
1. Physiological factors 
• Age 
• Ethnic groups 
• Menopause 
• High saturated fat diet 
2. Chemical compounds and drugs 
• Oestrogen 
• Progesterone 
• Growth hormone 
• Neomycin 
• Alcohol 
• Cyclosporin 
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3. Diseases 
• Myocardial Infarction 
• Renal Failure 
• Nephrotic Syndrome 
• Familial hypercholesterolemia 
PATHOPHYSIOLOGICAL LINK BETWEEN Lp [a] AND 
ATHEROTHROMBOSIS: 
 Accumulation of Lipoprotein[a] molecules has been demonstrated 
in arterial walls of coronary and cerebral vessels (6). The binding process 
is promoted by lipoprotein lipase or sphingomyelinase. Lipoprotein[a] 
particles are prone  to oxidative modification and scavenger receptor 
uptake, leading to intracellular cholesterol accumulation and foam cell 
formation (28) (29) which contributes to further atherogenesis. The high 
affinity of Lipoprotein[a] for fibrin provides a basis for frequent 
colocalisation in atherosclerotic plaques (30) (31). 
 In vitro studies indicate that lipoprotein[a] enhances the synthesis 
of plasminogen activator inhibitor 1 [PAI – 1] by endothelial cells. PAI – 
1 is the main inhibitor of fibrinolytic system (32). Another important 
action of Lipoprotein[a] is it reduces activation of latent transforming 
 7
growth factor β [TGE- β] by displacing plasminogen from surface of 
macrophages in atherosclerotic plaques. In absence of activated TGE – β, 
cytokines might induce smooth muscle cell proliferation and transform 
these cells into more atherogenic  cellular phenotype (33). 
 
RELATION BETWEEN Lp [a] AND ATHEROSCLEROSIS : 
 Recent  investigations have shown whether Lipoprotein[a] plays a 
primary or synergestic role in atherosclerosis (25) cross sectional and 
retrospective studies involving white men have shown increased risk of 
coronary and cerebrovascular atherosclerotic disease associated with 
plasma Lipoprotein[a] concentration greater than 80th centile [>250 -300 
mg/litre]. Recent prospective studies revealed a modest significant 
association between IHD and increased Lipoprotein[a] concentrations 
(34-35-36). Studies have shown that children with a positive family 
history of IHD commonly exhibit small apo [a] phenotypes (37) (38). 
This association of small apo [a] isoforms with higher Lipoprotein[a] 
concentrations suggests that raised Lipoprotein[a] concentration antedate 
the atherosclerotic process (25). 
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The pathophysiological correlation between Lp(a) and atherosclerosis is  
given below: 
1. Contributes to uptake of LDL and formation of foam cells 
2. Inhibits plasminogen activator and fibrinolysis leading to 
procoagulant tendency 
3. Release of cytokines 
4. Release of growth factors and smooth muscle cell proliferation 
5. Increased expression of adhesion molecules 
6. Endothelial dysfunction 
7. Interacts with other risk factors (eg) Homocysteine 
Lp [a] AND FIBRINOGEN: 
 Serum Lipoprotein[a] concentrations correlates well with plasma 
fibrinogen values in some studies (39) (40). This relationship is 
interesting because platelet activity is enhanced by fibrinogen (41) (42) 
and raised plasma fibrinogen concentrations are predictors of vascular 
events, both in healthy populations and inpatients with IHD (43). 
 There is a strong evidence that fibrinogen is an independent risk 
factor for ischemic atherothrombotic stroke (44). Fibrinogen values 
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remain raised after stroke and are associated with increased risk of 
recurrent vascular events (45). In patients with stroke, fibrinogen is 
associated with decrease in white blood cell elasticity and red blood cell 
deformity and an increase in plasma erythrocyte viscosity (46). 
Fibrinogen also promotes platelet aggregation and consumption in the 
ischemic area in patients with stroke (47). 
 In the above scenario fibric acid derivatives can decrease 
circulating concentrations of Lipoprotein[a] and fibrinogen (48) (49). So 
platelet inhibitory activity of fibric acid derivatives could be mediated via 
their action on lipid fractions [TG and HDL], Lipoprotein[a] and 
fibrinogen (50) (51). 
TRIGLYCERIDE CONCENTRATIONS AND STROKE: 
 Postprandial hypertriglyceridemia is associated with carotid artery 
atherosclerosis.Various epidemiological and cohort studies have reported 
elevated levels of serum triglyceride as an independent risk factor for the 
incidence of cerebrovascular accident  (52). 
HDL CHOLESTEROL AND STROKE: 
 Inverse association between HDL and stroke risk (13). Although 
no association was found in Framingham study (53) in the Copenhagen 
study (54) a negative relation was evident. 
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 Apart from well established risk factors for strokes [age, 
hypertension, diabetes, smoking, or presence of vascular disease] (55) the 
possibility that Lipoprotein[a] is a risk factor for ischemic stroke has been 
assessed in several studies (56, 57, 58, 59). 
 Studies supporting Lipoprotein[a] as a risk factor for stroke 
suggested that Lipoprotein[a] values were significantly [p<0.001] higher 
in patients with ischemic stroke compared with healthy individuals 
[median, 95 v 50 mg /lit]. This difference was also evident in a subgroup 
of subjects aged 30 to 69 yrs [p<0.001] . In another study it was found 
that TG and Lipoprotein[a] levels were increased in patients 6 months 
after stroke. Another study suggested that serum Lipoprotein[a] levels 
were increased in patients with stroke (60). Another study found that 33% 
patients Lipoprotein [a] values were raised but not related with 
cardiovascular or cerebrovascular characteristics or prognosis. 
 Silent cerebral infarction has also come into the limelight. A silent 
stroke is detected on imaging in patients with no neurological signs (61). 
These are predisposing factors for an overt stroke. In most cases, lacunar 
stokes of less than 1cm² in size are detected in basal ganglia in apparently 
healthy elderly people (62). These lesions are associated in most reports 
with advanced age and hypertension and constitute a major cause of 
dementia (62). Silent multiple lacunar strokes were associated with 
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hypercoagulable state, endothelial damage and a raised Lipoprotein[a] 
level. In atherosclerosis risk in community study Lipoprotein[a] with 
stroke was investigated and Lipoprotein[a] as an independent risk factor 
for stroke and TIA was shown (63). This evidence indicates that 
Lipoprotein[a] concentration is higher in patients with atherothrombotic 
brain infarction then in those with brain haemmorhage or lacunar 
infarction (64).Patients with ischemic heart disease are at increased risk 
of having stroke. 
ATHEROSCLEROSIS AND CEREBRAL ARTERIES: 
 Intracranial arteries are relatively resistant to cholesterol related 
endothelial damage (65,66,67). In studies primates failed to show a 
relationship between hyperlipidemia and development of atherosclerosis 
in intracranial arteries. Atherosclerotic lesions were more in carotid 
arteries and more extensive than those in basilar, vertebral, middle 
cerebral arteries. Coexistence of hypertension and hypercholesterolemia 
resulted in accelerated atherosclerosis of intracranial arteries in rat model. 
 Human necropsies have shown atherosclerosis changes in cerebral 
arteries make their appearance 20 years later than in the coronary arteries 
(68). Differences in the prevalence and extent of atherosclerotic lesions in 
aorta and coronary or cerebral arteries were observed between different 
age and race groups. Black individuals and older people tend to have 
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more extensive cerebral atherosclerosis (68). Pinocytic vesicles in 
endothelium of cerebral arteries, their rich innervation and the lower 
distending pressures make these vessels more resistant to hyperlipidaemia 
compared with coronary or peripheral arteries (68). 
 In a recent study Lipoprotein[a] values were associated with 
permanent cessation of flow and occlusive arterial thrombosis (69). 
Analysis of damaged arterial segments showed Lipoprotein[a] 
incorporation in the adventitia, media and intima. Plasma Lp[a] values 
correlated well with carotid atherosclerosis in subjects younger than 60 
years (70). Suggestions have also come up saying that apo[a] can cause 
endothelial dysfunction by enhancing lipid deposition in vessels, 
inhibiting fibrinolysis and modulating smooth muscle cell proliferation. 
Measurement of Lipoprotein[a] concentrations might help identify 
patients with an increased risk of stroke. Endothelial vasomotor tone is 
also related to implication of cerebral events (71) . 
FORMATION OF FOAM CELLS AND ATHEROSCLEROTIC 
PLAQUE: 
Atherosclerotic plaques but not normal human arteries contain 
Lp(a). Plasminogen-like lysine binding sites present on In a similar 
fashion, elastase cleaves Lp(a) in the same region to form F1 fragment 
and mini Lp(a), which is the F2 fragment connected to the LDL particle. 
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In vivo studies suggest that the F2 fragment is retained within the 
atherosclerotic plaque and is a potential cause for the atherothrombogenic 
action of Lp(a),1 whereas the F1 fragments may return to the circulation. 
Furthermore, following intravenous administration of Lp(a), F1- derived 
Apo(a) fragments can be isolated from plasma and urine of humans and 
mice. Indeed, enzymes such as metalloproteinases and elastases present 
within the atherosclerotic  plaque may contribute to this process and 
hence pathogenicity of Lp(a) by breaking it down into its F1 and F2 
fragments. 
MECHANISMS OF LIPOPROTEIN(a) INDUCED 
ATHEROGENESIS INDUCTION OF ADHESION MOLECULES 
ON VASCULAR ENDOTHELIAL CELLS: 
Lipoprotein(a) is believed to promote atherosclerosis by a number 
of separate but related mechanisms. Expression of adhesion molecules, 
VCAM-1 and E-selectin, on cultured human coronary endothelial cells is 
increased in the presence of Lp(a).It also induces human vascular 
endothelial cells to produce monocyte chemotactic protein (MCP), a 
potent chemoattractant for monocytes and a key cytokine implicated in 
the pathogenesis of atherosclerosis. Atherosclerosis is increasingly 
believed to be an inflammatory disease, and recruitment of monocyte 
macrophages is an important early step of atheroma formation. Within 
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days or weeks of feeding mice a high-fat and high-cholesterol diet, 
monocytes can be observed adhering to the surface of endothelial cells.  
The monocytes then migrate into the arterial intima .The Apo(a) 
molecule may play a key role in anchoring Lp(a) to the extracellular 
matrix within the arterial wall. Mutations affecting the lysine binding 
sites of kringle IV-10 of Apo(a) have been shown to decrease affinity of 
Lp(a) to the vessel  wall. Transgenic mice expressing mini Apo(a) 
containing a mutation in kringle IV-10 lysine binding sites have 
significant reduction in fatty streak formation and Lp(a) accumulation 
within the vessel wall. Klezovitch et al. have also demonstrated that 
proteoglycans within the vessel wall may play an important role in Lp(a) 
retention within the vascular intima.In these experiments, Apo(a), via its 
C-terminal domain, was found to bind to the protein core of the 
proteoglycan decorin, a proteoglycan synthesized by vascular endothelial 
and smooth muscle cells and present within atherosclerotic plaques.  
This binding was shown to be hydrophobic in nature and not 
dependent on the lysine binding sites on the Apo(a) molecule. However, 
the nature of the interaction between decorin and intact Lp(a) was an 
electrostatic binding of the glycosaminoglycan (GAG) portion of decorin 
to the ApoB100 of Lp(a). This decorin-Apo(a) interaction has recently 
been proposed by Klezovitch et al. as an explanation for preferential 
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vessel wall retention of Lp(a) over LDL. Within the diseased arterial 
wall, Lp(a) probably undergoes oxidative, proteolytic, and lipolytic 
changes induced by enzymes present within an atherosclerotic plaque, 
such as metalloproteinase, elastase, sphingomyelinase, and 
phospholipase. Oxidative modification by malondialdehyde, for instance, 
produces avid Lp(a) uptake by human monocyte-macrophages.  
Cholesterol loading of macrophages also results in marked 
enhancement of Lp(a) and Apo(a) internalization and degradation, 
revealing a lipid-driven mechanism for Lp(a) foam cell formation. 
Incubation of bovine aortic smooth muscle  cells with Lp(a) in the 
presence of lipoprotein lipase and sphingomyelinase lead to massive 
aggregation of Lp(a) on the surface of these cells, whereas coincubation 
with chondroitin ABC lyase prevented this aggregation, suggesting a key 
interaction with cellular proteoglycans. Moreover, coincubation of Lp(a)-
coated smooth muscle cells with mouse peritoneral macrophages led to 
formation of lipid-laden macrophages on the surface of these cells with 
disappearance of visible Lp(a) aggregates. This could be an important 
interaction between Lp(a), smooth muscle cells, and macrophages, 
leading to foam cell and plaque expansion.  
Enhancement of expression of cell surface adhesion molecules 
could be an important mechanism of Lp(a)’s atherogenecity. Other 
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investigators have shown that Lp(a) enhances expression of ICAM-1 in 
cultured human umbilical vein endothelial cells (HUVEC), although a 
similar effect with VCAM or E-select in has not been found. Moreover, 
neutralizing transforming growth factor beta (TGF) antibodies enhanced 
ICAM expression in HUVECs, while addition of recombinant 
TGF_inhibited the enhancement of ICAM-1 expression in Lp(a)-treated 
HUVECs, suggesting that enhancement of ICAM-1 expression by Lp(a) 
could in part be due to inhibition of TGF. This TGF mediated effect of 
Lp(a) has been well documented both in vitro and in vivo in animal 
models and in human subjects by Grainger et al. and provides a 
theoretical basis for Lp(a) effects on smooth muscle proliferation within 
the vessel wall. 
PLAQUE INFLAMMATION AND INSTABILITY: 
Novel mechanisms of Lp(a)-mediated plaque instability have been 
described recently. Human THP-1 macrophages produce interleukin-8 
(IL-8) in the presence of Lp(a), an effect primarily mediated by the C-
terminal region of Apo(a). Interleukin- 8 is a key inflammatory cytokine 
within atherosclerotic plaques and possesses chemotactic activity toward 
neutrophils,  T cells, monocytes, and smooth muscle cells, while 
decreasing macrophage expression of tissue inhibitors of 
metalloproteinases. Disinhibition of metalloproteinases that cleave 
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Apo(a) into F1 and F2 fragments  may increase inflammatory activity 
within plaque leading to rupture.  
The expression of urokinase and urokinase receptors on monocytes 
is also increased in a dose-dependent manner, resulting in increased 
plasmin generation. Increased protease availability may have multiple 
effects, including facilitation of cell migration and growth within plaque.  
Furthermore, monocyte adhesion to extracellular matrix (ECM) is 
facilitated by increased expression of micro PAR and ICAM-1, receptors 
for vitronectin and fibrinogen, respectively. Increased monocyte 
adherence to ECM and enhanced plasmin and urokinase activity could be 
important mechanisms of Lp(a)-mediated ECM degradation and plaque 
rupture. 
VASCULAR CELL PROLIFERATION: 
The induction of human smooth muscle cell proliferation by Lp(a) 
was first demonstrated in vitro by Grainger et al. 
This group showed that Lp(a) decreased generation of active TGF, 
an endogenous inhibitor of smooth muscle cell migration. Bovine 
pericytes and smooth muscle cells secreting TGF have also been shown 
to inhibit endothelial cell migration and repair of a denuded portion of a 
vessel in vitro. Antibodies to TGF abrogated the above-mentioned 
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inhibition, as did inhibitors of plasmin formation. This TGF effect is 
mediated by inhibition of plasminogen activation at the cell surface with 
subsequent inhibition of plasmin-mediated TGF activation. Furthermore, 
inhibition of TGF activation has been observed in Apo(a) transgenic mice  
and in human subjects with elevated Lp(a). Apo(a) transgenic mice have 
been shown to have threefold less active plasmin and significantly less 
active TGF_within the aortic wall than normal mice. Although the total 
TGF concentration was similar in sera from Apo(a) transgenic and 
normal mice, the proportion of total TGF in active form was significantly 
lower in the serum of Apo(a) transgenic mice. This TGF mechanism of 
dysregulated growth induced by Lp(a) is an attractive hypothesis for its 
effects on plaque growth. 
INHIBITION OF NITRIC OXIDE AND ENDOTHELIAL 
DYSFUNCTION: 
Nitric oxide (NO) has several pleiotropic antiatherogenic 
properties, including inhibition of T cell and smooth muscle proliferation, 
neutrophil adhesion, platelet activation,and reduction in endothelial 
permeability. It is not surprising that decreased NO synthesis has been 
associated with atherosclerotic  lesion development. Oxidized Lp(a) 
induces  dose-dependent reduction of inducible nitric oxide synthase  
(iNOS) protein expression and mRNA synthesis in lipopolysaccharide/ 
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interferon-stimulated mouse macrophages. Dose dependent inhibition of 
iNOS by Lp(a) may lead to increased atherogenesis. Elevated Lp(a) 
levels have also been associated with impaired endothelium-dependent 
vasodilatation in coronary arteries. 
In hypercholesterolemic children, flow-mediated dilation of the 
superficial femoral artery was inversely related to Lp(a),and in patients 
with elevated Lp(a) levels an increased vasoconstrictor response occurs 
after administration of L-NMMA, an NO synthase inhibitor.76 These 
combined effects suggest a compensatory increase in basal NO 
production by the endothelium in response to elevated Lp(a) levels.  
MECHANISMS OF THROMBOSIS: 
Lipoprotein(a) may promote a more thrombotic state by a number 
of mechanisms, including inhibition of the fibrinolytic system and 
enhancement of the tissue factor-mediated pathway.  
INHIBITION OF PLASMIN GENERATION: 
Apolipoprotein(a), as discussed previously, has significant 
structural homology with plasminogen. A varied number of cell types 
have been found to express cell surface receptors for plasminogen. Both 
intact Lp(a) and recombinant Apo(a) inhibit plasminogen binding to 
endothelial cells, cells, and platelets. The assembly and activation of 
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plasminogen on the endothelial cell surface has been studied extensively, 
and it is known that plasminogen binds to the surface of endothelial cells 
via a tissue plasminogen activator (t-PA)/plasminogen coreceptor, 
identified as a member of the annexin superfamily of proteins.81 In 
particular annexin II, which is selectively expressed on the endothelial 
cell surface, possesses independent binding domains for plasminogen and 
t-PA. Plasminogen appears to bind to the annexin receptor in a two  step 
process, whereby the N-terminal glutamine-plasminogen is converted to 
N-terminal lysineplasminogen by cleavage of a amino acid preactivation 
peptide with subsequent activation of the receptor in the second step.  
Tissue plasminogen activator binds to annexin at a separate site in 
close proximity to the plasminogen-binding site, leading to more efficient 
generation of plasmin. Lipoprotein(a) inhibits generation of plasmin on 
the endothelial cell surface without interfering with t-PA binding, and in a 
similar manner, Apo(a) inhibits plasminogen binding to annexin but has 
no effect on t-PA binding.  
Decreased plasminogen binding on the cell surface may therefore 
create an antifibrinolytic state. In addition, plasminogen activation by 
both streptokinase and t-PA has been shown to be impaired in the 
presence of Lp(a), and mice transgenic for Lp(a) are resistant to t-PA-
mediated lysis of artificially induced fibrin thrombi.  
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The mechanism for this action is believed to be in competition with 
plasminogen for binding to fibrin. It is interesting that plasmin catalyzes 
the binding of Lp(a) to immobilized fibrinogen and fibrin. The 
antifibrinolytic effect of Lp(a) is primarily defined by the size of the 
Apo(a) polymorphs, which display heterogeneity in their fibrin-binding 
activity.94 The affinity of each isoform depends on its size and plasma 
concentrations, with smaller size isoforms displaying higher affinity 
binding to fibrin.  
     The population most at risk for thrombosis, therefore, appears to 
be that possessing a predominant low molecular weight phenotype with 
high affinity for fibrin. Moreover, the Lp(a) phenotype (i.e., affinity for 
fibrin) may be more important as a determinant of risk than the actual 
plasma concentration of Lp(a). 
INCREASED EXPRESSION OF PLASMINOGEN ACTIVATOR 
INHIBITOR: 
Endothelial cell synthesis of plasminogen activator inhibitor- 1 
(PAI-1) is also increased by Lp(a).In cultured human endothelial cells, 
Lp(a) enhanced PAI-1 antigen activity and mRNA expression without 
altering t-PA activity. In addi- tion, monocytes derived from male 
patients with isolated Lp(a) hyperlipidemia, compared with those from 
healthy donors with normal Lp(a) levels, had increased upregulation of 
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PAI-2 mRNA and protein.This effect was gender specific, with no 
difference noted among females. Monocyte expression of PAI- 2 was also 
increased, another potential mechanism of an antifibrinolytic effect. 
Together these data suggest a mechanism whereby Lp(a) inhibits 
fibrinolysis at the endothelial cell surface and promotes thrombosis.  
INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR: 
Tissue factor pathway inhibitor (TFPI) is a Kunitz type serine 
protease inhibitor and a potent inhibitor of the tissue factor mediated 
coagulation cascade. Tissue factor pathway inhibitor is present on 
endothelial cells, activated monocytes, and platelets. However, the 
endothelium is believed to be the principal site of synthesis of TFPI. 
Tissue factor pathway inhibitor is expressed by vascular smooth muscle 
cells within atherosclerotic plaques, and TFPI within atherosclerotic 
plaque is associated with reduced tissue factor activity within the plaque.  
We have recently shown that Lp(a) binds and inactivates TFPI, 
potentially augmenting unopposed tissue factor (TF) effects. 
Lipoprotein(a) can bind and inactivate recombinant as well as cell-
associated TFPI in vitro in a dose-dependent manner. The LDL portion of 
Lp(a) isolated by dithiothreitol (DTT) reduction and gradient 
ultracentrifugation did not bind rTFPI, suggesting that this portion of 
Lp(a) was not important for binding. Apolipoprotein(a) bound to rTFPI in 
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a similar concentration-dependent manner as Lp(a). It is interesting that 
lysine plasminogen (L-Plg) was also found to bind to immobilized rTFPI 
but was inhibited by nanomolar concentrations of Apo(a) demonstrating a 
binding affinity that was lower than that of Apo(a).   
Furthermore, this dose-dependent inactivation of TFPI by Lp(a) in 
vitro and on endothelial cell surfaces was not affected by plasminogen. 
No Lp(a) dose dependent binding was seen when mutated forms of TFPI 
lacking the K3 domain or C terminus were immobilized instead of full 
length rTFPI demonstrating the importance of the C-terminal region of 
TFPI for this interaction.  
The binding of Apo(a) to rTFPI was shown to be lysine dependent 
and was inhibited by epsilon aminocaproic acid (EACA). This significant 
binding and inactivation of cell associated and recombinant TFPI by 
Lp(a) adds a further prothrombotic layer to the pleiotropic effects of this 
molecule. Thus, inhibition of TFPI within plaque at the endothelial 
surface and in the circulation may have additive effects in promoting 
thrombosis at the site of plaque rupture. 
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VASCULAR TISSUE AND CIRCULATORY EFFECTS: 
Discovery of new mechanisms suggest that the effects of Lp(a) 
within the vessel wall might be more relevant to its pathogenicity and 
different from its effects on circulating blood. Such differential effects 
might be a potential explanation for blood Lp(a) levels often not 
correlating with the incidence of coronary events. Cleavage of Lp(a) into 
potential atherogenic fragments, its retention by proteoglycans, and its 
induction of macrophage IL-8 expression are specific vessel wall 
atherogenic effects not seen to occur in peripheral blood. Moreover, Lp(a) 
causes increased plasmin activity within a plaque while decreasing 
circulating plasmin activity. These differential effects on blood and vessel 
wall may be additive in terms of atherothrombotic risk, potentially 
facilitating plaque rupture and later thrombosis on the luminal surface of  
the vessel.  
STUDIES NOT SUPPORTING Lp  [a] AND STROKE: 
 In a study of 90 patients with stroke or TIA of atherothrombotic 
origin where lipid variables were measured including Lipoprotein[a], no 
significant difference in Lipoprotein[a] concentrations or distribution of 
apo E phenotypes among patients and controls was obtained (72). In a 
prospective study in Finland no association was found between 
Lipoprotein[a] and atherosclerotic disease [myocardial infarction or 
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stroke] (73). A study of middle aged white physicians was also conducted 
in which Lipoprotein[a] samples were collected together with paired 
controls, matched for age and smoking habits and no association was 
found between plasma concentration of Lipoprotein[a] and future risk of 
total or thromboembolic stroke was found (74). 
 Even a moderate rise in circulating concentration of homocysteine 
is said to be associated with an increased risk of Cerebrovascular 
accident. There has also been evidence suggesting that Lipoprotein[a] 
levels and homocysteine levels when increased concomitantly can cause 
stroke. These will have an unwanted effect on the platelets and as well as 
on the coagulation profile and fibrinolysis. 
Increase in homocysteine by itself causes increased platelet 
aggregation and predisposes to ischaemic stroke. The homocysteine 
concentrations are influenced by renal and Vit B12 status in patients with 
stroke. Homocysteine and Lipoprotein[a] act together to promote 
atherosclerotic activity. Clustering of all these factors increased chances 
of vascular events. Epidemiological studies have indicated that 
dyslipidemia, raised fibrinogen and increased Lipoprotein[a], increases 
chances of vascular events. 
 Plasma concentration of Lipoprotein[a] and cholesterol, 
triglycerides and VLDL are higher in patients with hypertension. It has 
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been shown that increased Lipoprotein[a] with low molecular weight 
apo[a] isoforms are strong and independent risk factors for strong and 
independent risk factors for IHD in patients with hypertension. 
 The data on Lipoprotein[a] concentrations in diabetes are based on 
smaller studies and are conflicting. Larger studies and those including 
apo [a] phenotype analysis suggest that Lipoprotein[a] concentrations are 
not different from those in patients without diabetes at are said to he 
moderately increased in patients with diabetes. However it has been 
shown that Lipoprotein[a] concentration is increased in patients with 
diabetes and renal impairment. Further atherosclerotic complications in 
patients with diabetes are associated with higher Lipoprotein[a] 
concentrations. 
          Cigarette smoking is associated with increase in LDL , TG and 
VLDL and lowering of HDL. No direct effect of Lipoprotein[a] in 
smokers has been ascertained. The effect of obesity on Lipoprotein[a] 
levels is also not fully proved. Whereas are study says that there is no 
relation between obesity and Lipoprotein[a] levels another study says that 
reduction in Lipoprotein[a] levels was present when weight was reduced. 
The mechanism by which this change has occurred is not known. 
Apolipoprotein E[apo E] have also been associated with strokes. The apo 
E4 gene is high in patients with ischemic stroke. However the apo E3 /E3 
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phenotype has a protective association with stroke. The apo E2 genotype 
is a risk factor possibly expressed through obesity, diabetes, and 
hypertension. Lipoprotein[a] level in stroke may rise even immediately 
after stroke.  
          Under normal condition Lipoprotein[a] level remains remarkably 
constant throughout life. Lipoprotein[a] level is also increased in patients 
with chronic stroke and myocardial infarction. Change in Lipoprotein[a] 
levels is based on changes in production and not on the catabolic activity. 
Changes in Lipoprotein[a] in cardiac disease is said to be associated with 
changes in other lipoprotein levels. In lacunar strokes, Lp[a] level was a 
not found to be elevated compared to cortical infarcts. 
ROLE OF Lp(a) IN MACROVASCULAR DISEASES: 
          Association of Lp(a) and coronary artery disease (CAD) was first 
observed in 1974. The accumulated data have established it as an 
important inherited risk factor for the macrovascular diseases like CAD, 
cerebrovascular accident and peripheral vascular diseases. Several case 
studies have shown an association of elevated Lp(a) plasma 
concentrations with premature coronary atherosclerosis and myocardial 
infarction. Lp(a) is considered to be ten times more atherogenic than 
LDL-C. Relative risk of CAD is increased three –fold if the levels of 
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Lp(a) are more than 30mg/dl. Serum Lp(a) levels have shown to correlate 
well with the presence, extent, severity and score of atherosclerotic 
lesions on coronary angiography.  
          The Scandinavian Simvastatin Survival study provides independent 
confirmation that a high Lp(a) level is a significant CAD risk factor. In 
Quebec cardiovascular study, however, Lp(a) was not a significant risk 
factor for CAD but appeared to increase the risk associated with other 
lipid risk factors. Lp(a) has been noted to be an independent risk factor 
for peripheral vascular disease. 
RELATIONSHIP BETWEEN Lp(a) AND LIPID AND NON-LIPID 
RISK FACTORS 
          Correlation co-efficients of Lp(a) ranged from 0.16 to 0.17 for total 
cholesterol,LDL-C,HDL-C, serum triglycerides, apo A-1, apo A- II, apo 
– B and truncal fat . Atherogenic risk appears to be increased when there 
is a cluster of lipid abnormalities. Effects of serum Lp(a)   on 
atherogenesis are increased by high LDL-C and low HDL-C levels. Men 
with LDL-C values of more than 317 mg/dl and Lp(a) values of more 
than 30 mg/dl have a sixteen-fold increase for CAD. High levels of Lp(a) 
were found to increase the risk associated with hyperhomocysteinemia by 
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a factor of nine and  a simultaneous elevation in having an odds ratio of 
31 for CAD. 
 Lp(a) AND DIABETES 
          In diabetes, conflicting reports are available regarding prognostic 
significance of Lp(a) levels. A few studies record that it may be elevated 
in insulin dependent diabetes mellitus. Particularly ipatients with 
microalbuminuria and proliferative retinopathy show higher Lp(a) 
levels.South Indian non-insulin dependent diabetes patients with high 
Lp(a) levels, however show good correlation with CAD. 
REDUCTION OF Lp[a]: 
 Saturated and n-3 polyunsaturated fatty acids may slightly reduce 
Lipoprotein[a] values. Palm oil rich diet has shown to marginally 
decrease the Lipoprotein[a] levels (12). Nicotinic acid is also said to have 
a mild effect in reducing the Lipoprotein[a] levels. 
 Statins is said to cause a mild increase in Lipoprotein[a] level, the 
fact that statins does not reduce Lipoprotein[a] is because LDL receptor 
does not play a major role on the catabolism of Lipoprotein[a]. 
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ROLE OF FIBRATES: 
 Fibric acid derivatives exert a  favourable effect on TG/HDL 
concentrations and also on LDL quantity and quality. Fibrates reduce 
fibrinogen and possibly Lipoprotein[a] values. A reduction in firbrinogen 
concentrations was associated with decrease in incidence of primary end 
points cardiac death and stroke (15). Another possibility is a fibrate 
induced reduction in oxidized LDL production because this form of LDL 
is very atherogenic. Gemifibrozil reduced stroke by 1.8% [ in treated 
group]. 
 Body weight and tight glycemic control has a beneficial and major 
impact on the Lipoprotein[a] levels in patients who are diabetics. In the 
diabetics the triglycerides metabolism is impaired [especially in type 2 
diabetes]. Treating dyslipdemia in  diabetic patients improves the lipid 
profile and lowers chances of vascular events. 
 Antihypertensive can affect plasma fibrinogen and Lipoprotein[a] 
values as well as lipid parameters (76) due to the above factors the choice 
of medication in people with those predictions of vascular events [stroke] 
are raised (76). Hormone replacement therapy favourably affects 
Lipoprotein[a] level. Thyroid replacement treatment has also shown a 
decline in Lipoprotein[a] levels probably due to the effect on apo[a] 
production or Lipoprotein[a] assembly (28). 
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FUTURE TRENDS: 
Lipoprotein(a) is now established as a genetically determined 
predictor of atherosclerotic vascular diseases and in particular, CAD. 
High levels of this lipoprotein , particularly in Asian Indians, is a matter 
of clinical concern. Since it is not generally amenable to the lifestyle 
measures, other lipid and non-lipid risk factors must be modified to 
decrease the risk in those with high Lp(a) levels. 
 The Lipoprotein[a] undergoes more changes after its entry into the 
arterial wall whether these changes cause changes on vascular events is 
yet to be ascertained. Studies assessing risk of lipoprotein[a]  must also 
consider the contribution of other factors like dyslipidemia, hypertension, 
fibrinogen and homocysteine. The contribution of above factors may also 
have high association with increased Lipoprotein[a] values and 
atherosclerosis and hence more research is required in this area. 
          The estimation of Lp(a) levels is a useful tool for guiding 
management strategy in the individuals with  
1. Family history of premature CAD 
2.  Normal total cholesterol and evidence of macrovascular 
disease 
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3. Isolated hypertriglyceridemia 
4. Those belonging to high risk ethnic group 
 
Genetic and environmental factors controlling circulating 
concentration of Lipoprotein[a]  need further evaluation. With the given 
drugs the reduction of Lipoprotein[a] might prove difficult but dealing 
aggressively with all other risk factors associated with Lipoprotein[a] is 
the plan of the hour. 
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MATERIALS AND METHODS: 
 This study was carried out in thirty-eight patients presenting with 
ischemic stroke who also had associated diabetes mellitus and who were 
admitted in the medical intensive care unit, intermediate medical care unit 
and medical wards of PSG Hospitals, Coimbatore. 
AIM OF THE STUDY; 
 The aim of the study is to evaluate the lipoprotein [a] levels in 38 
cases of diabetic patients who presented with ischemic stroke and to 
determine the consistency of its association when compared with 38 
diabetic patients without stroke as controls. 
INCLUSION CRITERIA: 
- Patients who presented to the hospital with ischemic stroke and 
who were known diabetics. 
- The diagnosis of cerebral infarction was confirmed by clinical 
signs and symptoms, history of the disease and cerebral 
computerized axial tomography. 
- Type II diabetes mellitus had been previously diagnosed. 
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EXCLUSION CRITERIA: 
 Patients with any of the following were not eligible for the study, 
1. Past history of coronary artery disease. 
2. Abnormal renal function. 
3. Smokers. 
4. Old Cerebrovascular accident. 
5. Known Hypertensive. 
DETERMINATION OF LIPOPROTEIN[a]: 
 Blood samples for the control group was taken after 12 hrs of 
overnight fasting under aseptic precautions. 
 Blood samples for the ischemic stroke  patients were taken before 
administering heparin for the patient under aseptic precautions. 
 Lipoprotein[a] level was measured by the enzyme immunoassay 
using a monoclonal antibody against lipoprotein[a]. 
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PROFORMA FOR THE STUDY: 
 Lipoprotein [a] in stroke patients with diabetes mellitus / 
Control. 
Name :   Age :  Address: 
Ip.No:   Sex : 
Date of Admission :  Date of Discharge: 
Presenting Complaints:        Others: 
Examination: 
Bp:    Pulse:   Rhythm: 
Examination of CNS: 
Examination of other systems: 
Any complications in 1st 24 hrs: 
INVESTIGATIONS: 
CT Brain :           ECG :  RBS:       Urea: 
Electrolytes:     Creatinine: 
Urine Routine:     HbA1C: 
Chest X-ray[bedside]:    CBC: 
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RESULT AND ANALYSIS 
Sex and age distribution 
The sex and age of all the subjects are given in table 1. 
TABLE 1 
SEX AND AGE OF THE SUBJECTS IN THE STUDY GROUP 
AND THE CONTROL GROUP 
Study group Control group 
S.No 
Sex Age (yrs.) Sex Age (yrs.) 
1.  MALE 60 MALE 45 
2.  MALE 60 MALE 50 
3.  MALE 52 MALE 39 
4.  FEMALE 71 MALE 55 
5.  MALE 65 FEMALE 50 
6.  MALE 48 FEMALE 58 
7.  MALE 50 MALE 37 
8.  MALE 39 MALE 40 
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9.  MALE 63 FEMALE 45 
10. FEMALE 69 MALE 62 
11. FEMALE 70 MALE 55 
12. MALE 59 FEMALE 54 
13. MALE 52 FEMALE 69 
14. MALE 47 MALE 65 
15. MALE 53 MALE 55 
16. MALE 67 MALE 63 
17. FEMALE 60 MALE 62 
18. MALE 64 MALE 70 
19. MALE 66 MALE 64 
20. MALE 69 MALE 61 
21. MALE 64 MALE  52 
22. MALE 49 MALE 57 
23. MALE 57 MALE 63 
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24. MALE 46 FEMALE  55 
25. MALE 63 MALE  52 
26. MALE 74 FEMALE  47 
27. MALE 74 FEMALE  42 
28. FEMALE 76 FEMALE  57 
29. MALE 58 MALE 60 
30. MALE 55 MALE 58 
31. MALE 58 MALE 60 
32. MALE 48 MALE 62 
33. MALE 52 MALE 51 
34. MALE 64 MALE 49 
35. MALE 68 MALE 45 
36. FEMALE 67 MALE 37 
37. MALE 70 FEMALE  54 
38. MALE 74 MALE 59 
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          The subjects involved in the study were from both the sexes and the 
age of the subjects ranged from 35 – 80 years. The number, sex 
distribution , age range and the mean age of the subjects belonging to the 
study group and the control group are given in table 2. 
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TABLE -2  
NUMBER, SEX, AGE RANGE AND MEAN AGE OF THE 
SUBJECTS  
Sex 
Groups 
Number 
of 
subjects Male Female 
Age 
range 
(yrs.) 
Mean age ± 
SD 
Study  38 32           (84.2) 
6          
(15.7) 35-80 63.18±8.62 
Control  38 28                (73.6) 
10                 
(26.3) 35-80 56.55± 9.47 
Figures in parenthesis indicate percentage of subjects  
          There was an equal distribution of subjects in both the groups 
(n=38).The percentage distribution of male subjects was higher in both 
the groups compared to that of the female subjects. The mean age of the 
subjects in the study group was found to be higher (63.18 years) 
compared to that of the control group (56.55 years) subjects. 
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TABLE – 3 
SERUM LIPOPROTEIN [a] LEVELS OF THE STUDY SUBJECTS 
[DIABETIC WITH ISCHEMIC STROKE]                          
[NORMAL VALUE < 30 mg/dl] 
S.NO Serum lipoprotein[a] levels  ( mg/dl ) 
1 62.8 
2 40.9 
3 51.7 
4 90.8 
5 38.4 
6 20.3 
7 64.6 
8 56.8 
9 88.5 
10 64.8 
11 50.5 
12 18.3 
13 80.2 
14 16.2 
15 53.0 
16 76.8 
17 55.8 
18 48.6 
19 66.0 
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20 36.8 
21 57.4 
22 42.0 
23 30.0 
24 26.0 
25 27.5 
26 42.4 
27 38.0 
28 31.0 
29 24.0 
30 29.6 
31 32.0 
32 31.8 
33 52.4 
34 38.4 
35 36.2 
36 28.0 
37 29.6 
38 33.4 
Mean ± SD = 45.03  ± 19.19 mg/dl 
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TABLE- 4 
SERUM LIPOPROTEIN [a] LEVELS OF THE CONTROL 
SUBJECTS [ DIABETES] 
S.NO Serum lipoprotein[a] levels ( mg/dl) 
1 21.6 
2 38.5 
3 28.6 
4 8.0 
5 15.5 
6 36.8 
7 5.6 
8 40.6 
9 28.6 
10 22.5 
11 18.2 
12 53.2 
13 20.2 
14 12.7 
15 33.8 
16 10.0 
17 24.8 
18 30.2 
19 12.8 
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20 14.0 
21 24.4 
22 26.7 
23 30.6 
24 34.0 
25 28.4 
26 26.6 
27 20.6 
28 18.8 
29 26.0 
30 32.6 
31 28.6 
32 24.8 
33 30.0 
34 12.2 
35 14.4 
36 15.6 
37 16.6 
38 12.2 
Mean ± SD = 23.66 ± 9.40 mg/dl. 
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TABLE- 5 
COMPARISON OF THE SERUM LIPOPROTEIN (a)     LEVELS 
BETWEEN THE STUDY AND CONTROL GROUPS 
GROUPS 
NUMBER 
OF 
SUBJECTS 
MEAN ± 
SD ‘t’ value 
Level of 
significance 
STUDY 38 45.03±19.19 
CONTROL 38 23.66±9.40 
5.54 p<0.001 
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DISCUSSION: 
 The mean level of Lipoprotein [a] obtained in patients with stroke 
and diabetes mellitus was 45.03±19.19 mg/dl and that of the control 
group was 23.66±9.40 mg/dl. 
 On comparing both the groups,  it was found out that the 
differences were found to be statistically very significant (t=5.54) and the 
level of significance was p<0.001. 
 Maurus marques de Almedia Holanda et al in their study conducted 
in 60 patients had found out that Lipoprotein[a] levels are significantly 
higher in ischemic stroke patients than in controls. They concluded 
saying that a reduction of Lipoprotein[a] levels was important in 
clinically managing patients with stroke. 
 Van Kooten and colleagues assessed the Lipoprotein[a] levels in 
151 patients admitted with acute cerebral ischemia, they found out that 
about 33% of the patients had a significantly elevated plasma lipoprotein 
[a] level, but this was not associated with stroke characteristics or 
prognosis. 
 47
 Nagayama et al in a case control study investigated lipoprotein[a] 
values in patients and found out that Lipoprotein[a] levels was an 
independent risk for ischemic stroke and not for lacunar stroke. 
 Peng et al studied the relation between lipids, apo E genotypes and 
risk of ischemic stroke. 180 patients were enrolled in this study. 90 
patients had experienced acute ischemic strokes and 90 were healthy 
individuals. The study concluded that serum Lipoprotein[a] 
concentrations and apo E 4 genotype were prominent lipid predictors for 
ischemic stroke in addition to more established factors such as 
hypertension, family history of stroke and cigarette smoking. 
 In the atherosclerosis risk in communities ARIC [study the 
association of Lipoprotein[a] with stroke was investigated in 15160 
people. In this study, Lipoprotein[a] was found to be an independent risk 
factor for strokes and transient ischemic attacks. Blacks and whites 
participated in this study and Lipoprotein[a] levels was not found to have 
any racial differentiation [ i.e. Lipoprotein[a] associated stroke morbidity 
was not influenced by race]. This evidence proves the elevated level of 
Lipoprotein[a] is higher in atherothrombotic brain infarction than in those 
with brain haemmorhage or lacunar infarction. 
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 In a study done by Jurgens and Koltringer the Lipoprotein[a] 
values were significantly higher in patients with ischemic stoke compared 
with healthy individuals. 
 Vavernova et al investigated Lipoprotein[a] value in 45 patients 
with stroke and their first degree relatives. They reported that 
Lipoprotein[a] values were genetically conditioned in patients with 
ischemic strokes. 
 However there have been few studies which demonstrated no 
relation between Lipoprotein[a] and atherosclerotic disease to quote a few 
studies. 
 Alfthan et al in a study of 7424 men and women concluded that no 
relation was there between Lipoprotein[a] and stroke. 
 Ridker PM, et al in a study of 14916 people concluded saying that 
no association between baseline plasma concentration of Lipoprotein[a] 
and future risk of all types of stroke was found. 
 However to find out in totality  whether Lipoprotein[a] is an 
independent risk factor or not many studies with large numbers of people 
with proper inclusion and exclusion criteria will have to be done to come 
to a final conclusion. 
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SUMMARY AND CONCLUSION: 
 This study was carried out on 38 patients with diabetes mellitus 
who presented with ischemic stroke and who were admitted in the 
medical intensive care unit, intermediate medical care unit and medical 
wards. 
 Lipoprotein [a] was estimated by using the enzyme immunoassay 
using a monoclonal antibody against the Lp[a]. 
 The lipoprotein [a] levels in this study [ ischemic stroke with 
diabetes mellitus] group were found to be significantly [p<0.001] higher 
than those of the control group. The mean values of Lp(a) for patients 
with diabetes mellitus and ischemic stroke was 45.03±19.19 mg/dl and 
that of the  control group was  23.66 ± 9.40 mg/dl. 
 Literature review in connection with the study revealed many 
studies which demonstrated the independent effects of increased 
lipoprotein [a] as a cause for ischemic stroke irrespective of diabetes 
mellitus. Many small and large studies have demonstrated the hazardous 
effects of increased lipoprotein [a] in patients with stroke. 
 The present study showed that patients with ischemic stroke with 
diabetes mellitus had higher lipoprotein [a] levels when compared to the 
control group [diabetic patients]. This goes to show that lipoprotein [a] is 
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an independent risk factor for stroke, and measures have to be taken to 
lowers the level of lipoprotein[a]. 
 A diet rich in palm oil has been reported to reduce Lipoprotein[a] 
concentrations by 10% (77). 
 Fibrates also have an effect in reducing the Lipoprotein[a] level. 
 Hormonal replacement therapy in women was found beneficial in 
reducing Lipoprotein[a]. 
 The findings of this study has clearly brought to light the 
significance of Lp(a) as an independent risk factor for the incidence of 
cerebrovascular disease. 
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